首页工具

搜索结果

Search Results for " l-pgds "

如果没找到您满意的产品或者您对产品有其他要求，可以联系我们专业顾问为您提供针对性的合理建议。 QQ咨询网站留言咨询

Cat. No.	Product Name	Target	Signaling Pathways
T1866	AT-56	Others; PGE Synthase	Immunology/Inflammation; Others
	AT56 是口服有活性的脂钙蛋白型前列腺素 D 合酶 (L-PGDS) 选择性抑制剂，其IC50=95 μM，Ki=75 μM。它能够特异性地抑制L-PGDS 催化的 PGD2介导的嗜睡或疼痛反应。
T1804	HPGDS inhibitor 1 HPGDS-inhibitor-1	PGE Synthase	Immunology/Inflammation
	HPGDS inhibitor 1 是口服具有活性的HPGDS 选择性抑制剂，在酶和细胞分析中的IC50值分别为 0.6 nM 和 32 nM，但对 L-PGDS、mPGES、COX-1、COX-2 、5-LOX 无抑制作用。
T15503	HQL-79	Others	Others
	HQL-79 is a selective and orally active human hematopoietic prostaglandin D synthase (H-PGDS) inhibitor. It inhibits the synthesis of PGD2 and acts as an anti-allergic agent (Kd: 0.8 μM and IC50: 6 μM). It also shows no obvious effect on COX-1, COX-2, m-P
T38350	TAS 205
	TAS 205 is an inhibitor of hematopoietic prostaglandin D synthase (H-PGDS; IC50= 55.8 nM).1It is selective for H-PGDS over lipocalin-type PGDS (L-PGDS) at 100 μM, as well as over enzyme and receptor panels at 10 μM. TAS 205 inhibits production of prostaglandin D2induced by A23187 in KU812 human and RBL-2H3 rat basophils with IC50values of 78.3 and 181.3 nM, respectively. It inhibits ovalbumin-induced nasal lavage fluid eosinophil infiltration and late-phase nasal obstruction in an ovalbumin-sens...